GlobeNewswire·Oct 7, 2025, 8:30 AM ET

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Aligos Therapeutics announced eight presentations, including one oral session, at The Liver Meeting 2025 in Washington, D.C. from November 7 to 11, 2025.
The company will present data on ALG-000184, a potential first- or best-in-class small molecule CAM-E for chronic HBV infection, showing potent HBV DNA suppression in treatment-naive subjects.
Professor Man-Fung Yuen from the University of Hong Kong will present oral data on ALG-000184 and poster data on sustained HBV antigen reduction after 96 weeks of treatment.
Algos will share preclinical findings on ALG-001075, a capsid assembly modulator that prevents cccDNA formation, HBV DNA integration, and directly targets HBeAg.
Additional preclinical abstracts cover the differentiation of HBV capsid assembly modulators, the differential effects of CAM-E and CAM-A compounds on core proteins, and lead optimization for a potential best-in-class HBV ASO.
The company will present two pre-clinical short interfering RNA molecules targeting human HSD17beta13 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
All abstracts are available on the AASLD website at https://www.aasld.org/the-liver-meeting.
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases, viral infections, and coronaviruses.